To address the issues of stability and permeability, Yadav et al.[47▪] have developed an antibody delivery platform composed of two features: a pH-sensitive coating, released only when exposed to specific pH and/or colonic bacteria, and a core consisting of amino acid-based excipients mixed with IL-6 antibodies (IL-6 is elevated in IBD patients) [48]. This evidence concerns the gene IL6 and inflammatory bowel disease.